1,720,978 research outputs found
Risposta Virologica Sostenuta dopo terapia anti-HCV in paziente con neuropatia di Charcot Marie Tooth tipo 1
No full textCirca 170 milioni di persone nel mondo sono affette da epatite cronica C, la cui terapia si basa sull’associazione di Interferone peghilato (pegIFN) e Ribavirina (RBV) che permette tassi di eradicazione del 75-90% per i genotipi 2 e 3 e del 45-50% per i genotipi 1 e 4. La presenza di comorbidità (cardiovascolari, psichiatriche, neurologiche ecc.) in tali pazienti limita applicabilità ed efficacia del trattamento standard anti-HCV, spesso gravato anche da severi effetti collaterali. Importante in questi casi considerare la presenza di eventuali fattori predittivi di risposta (es. genotipo 2 o 3, bassa viremia basale) oltre alla motivazione del paziente prima di intarprendere il trattamento.
Descriviamo il primo caso di un paziente affetto da neuropatia di Charcot Marie Tooth (CMT), rara neuropatia motorio-sensitiva, e disturbo ossessivo compulsivo, trattato con successo per epatite cronica C
Brain Abscess Sustained by Actinomyces meyeri in an Immunocompetent Patient
No full textActinomycosis is a rare granulomatous disease, caused by filamentous Gram positive anaerobic bacteria,
which may become pathogenic following disruption of anatomical barriers with invasion of host’s deep tissues and
dissemination of infection to any site of the organism. A. israelii is found in most clinical presentations.
We describe a case of a 41 years-old immunocompetent woman affected by thalamic abscess due to Actinomyces
meyeri, presenting with fever, headache, vomit, confusion. A brain Computed Tomography (CT) and a Magnetic
Resonance Imaging (MRI) revealed an expansive thalamic lesion with wide central necrosis and perilesionaledema.
The patient was immediately addressed to a first evacuation of the mass, followed by a second drainage because of
recurrence of the abscess. Microbiological and histological findings from intraoperatory specimens, resulted positive
for A. meyeri. Ampicillin 20 g plus rifampicin 1200 mg/day was started, followed by ceftriaxon 4 g/day for 2 weeks and
by amoxicillin 3 g/day. The treatment was discontinued after 9 months; brain MRIs performed at the end of therapy
and after 3 and 6 months from the interruption of therapy revealed a gradual but complete resolution of cerebral
abscess.
Actinomycosis is an infrequent but severe disease that can mimic tuberculosis, nocardiosis and malignancies.
Cases of cerebral actinomycosis reported in literature are limited, but those from A. meyeri are extremely rare.
Moreover this pathogen is often related to disseminated disease, especially in immunocompromised patients. There
is no consensus about treatment of cerebral actinomycosis: different types of regimens are proposed; we firstly
administered ampicillin (12-16 g/day for at least six months), plus rifampicin, to enhance their penetration in CNS.
Actinomycosis requires a prompt diagnosis and antibiotic treatment (often in combination with surgery) in order to
avoid dissemination and prevent complications
Tuberculosis Reactivation in a Patient with Chronic HBV Infection Undergoing PEG-Interferon Therapy: Case Report and Literature Review
No full textPegylated (PEG) -interferon therapy is a first-line choice to treat both chronic hepatitis B and C. Its side effects
are well known and include fatigue, anaemia, weight loss, neuropsychiatric disorders, immune disregulation and white
blood cells decrease. All these events could play a role in reactivation of a latent tubercular infection (LTBI), and some
authors reported development of Tuberculosis (TB) during anti-HCV treatment with PEG-interferon and ribavirin.
We report here the first case of TB reactivation during PEG-interferon monotherapy for HBV in a Chinese man, managed
with interruption of interferon and starting of a therapy with a nucleotide analogue, in combination to anti-tubercular
standard regimen, which led to a successful treatment of both diseases without significant side effects. Our report
highlights the need of increasing the control of TB, by diagnosing and treating people with latent tubercular infection, that add up to one third of global population, in particular those with a high risk of reactivation
Infezione cutanea disseminata da Mycobacterium Kansasii in paziente con leucemia linfatica cronica
No full textPremesse: Mycobacterium kansasi è un micobatterio atipico responsabile di quadri polmonari anche gravi, soprattutto in pazienti compromessi (BPCO) o immunocompromessi (HIV, neoplasie, chemioterapie).
Obiettivo: riportiamo il caso di un paziente affetto da leucemia linfatica cronica (LLC), con infezione disseminata cutanea da M. kansasii associata ad interessamento polmonare.
Risultati: il paziente giungeva alla nostra osservazione per la comparsa da alcuni mesi di una lesione ulcerata, secernente e dolente a livello della coscia sinistra, associata a tosse poco produttiva. Dall'anamnesi emergeva puntura di insetto nella sede della lesione e storia di leucemia linfatica cronica plurirefrattaria, in trattamento con steroide a basse dosi. Gli esami ematici mostravano linfocitosi assoluta, PCR <0.4 mg/dl. Il paziente era apiretico e in discrete condizioni generali; negative sierologie per HIV, toxoplasma, lue, CMV. Test QuantiFERON positivo.
L'esame istologico della lesione mostrava tessuto fibroso e macrofagi a citoplasma zaffato da bacilli PAS positivi e Ziehl-Neelsen positivi mentre le colture dalla lesione e dall'escreato risultavano positive per M. kansasii, resistente a isoniazide. RX torace e TC torace erano negativi.
Si iniziava pertanto terapia con Rifampicina (600 mg die), Claritromicina (500 mg x 2 die) ed Etambutolo (400 mg x 3 die), con guarigione completa dell'ulcera e scomparsa della tosse. Durante il ricovero si è assistito anche a riacutizzazione della LLC, per cui si riprendeva terapia immunosoppressiva con Ibrutinib. Attualmente il paziente ha completato 6 mesi di terapia (durata prevista del trattamento, 12-18 mesi), con ottima tollerabilità.
Conclusioni: le micobatteriosi non tubercolari rappresentano patologie ubiquitarie, sostenute da microrganismi il cui serbatoio è prevalentemente ambientale. Nel paziente immunocompromesso non è raro riscontrare forme disseminate da M. kansasii, contraddistinte soprattutto da un coinvolgimento polmonare. Nel nostro caso tuttavia, la localizzazione cutanea è stata predominante, mentre il quadro polmonare, del tutto secondario. Rari sono i casi di coinvolgimento cutaneo da M. kansasii riportati in letteratura: Ad oggi, le descrizioni di localizzazione extrapolmonare da M. kansasii, riguardano in prevalenza forme settiche ed osteo-articolari in pazienti con patologie reumatiche (borsiti, tenosinoviti), mentre solo 4 (dal 2003), pazienti HIV positivi o con co-morbidità ematologica. Nel nostro caso resta da chiarire se l'interessamento cutaneo sia stato conseguente alla puntura di insetto contaminatasi con le secrezioni respiratorie infette, o se esso stesso sia stato fonte di successiva disseminazione ematogena al polmone. L'infezione da M. kansasii dovrebbe sempre sospettata in paziente ematologici, anche in caso di quadri clinici non usuali, come quello cutaneo
ERITEMA DI BAZIN E TB LINFONODALE: UN LUNGO PERCORSO DIAGNOSTICO
No full textPREMESSA: L’eritema induratum di Bazin è una rara condizione clinica cronica caratterizzata da noduli sottocutanei dolorosi, con tendenza all’ulcerazione, recidivanti, a carico delle gambe, prevalente nel sesso femminile, che pare essere associata ad una reazione di ipersensibilità ad antigeni micobatterici e quindi a pregressa infezione tubercolare.
OBIETTIVO: Descriviamo il caso di una donna di 76 anni, affetta da grave obesità, ipertensione arteriosa e coxartrosi, che giungeva alla nostra osservazione nel Gennaio 2011 per recidiva di Eritema di Bazin diagnosticato in altro centro (biopsia cutanea delle lesioni agli arti inferiori), come dermatite granulomatosa gigantocellulare. Dal 2006, la paziente aveva effettuato 3 cicli di terapia antitubercolare (2006: Isoniazide (INH) + Etambutolo (EMB) per 6 mesi; 2008 Pirazinamide (PZA)+Rifampicina (RMP)+ EMB+ INH interrotto per intolleranza a RMP; 2009, INH+ Prulifloxacina+ EMB per 5 mesi) a dosaggi adeguati, con risoluzione temporanea del quadro e recidiva al termine di ogni ciclo. All’ingresso nel nostro DH, la paziente presentava lesioni nodulari eritematose dolorabili ed edemi improntabili alle gambe bilateralmente, in assenza di sintomi sistemici. La restante obiettività era nei limiti. L’anamnesi familiare era positiva per TB (padre deceduto per TB polmonare).
Gli esami di laboratorio, peraltro nei limiti, mostravano lieve rialzo di PCR (1.80 mg/dl) e positività ad alto titolo (1:640) di Anticorpi anti-Nucleo. I markers neoplastici, le sierologie per HBV, HCV, HIV e test IGRA erano negativi. Nel tentativo di confermare la diagnosi di Eritema di Bazin, si sottoponeva la paziente a biopsia cutanea (che confermava il precedente quadro istologico, con negatività degli esami microbiologici per ricerca di micobatteri), e a TC del torace con riscontro di nodularità periferica polmonare sinistra, su cui non si eseguiva campionamento trans-toracico per le sue piccole dimensioni. La fibrobroncoscopia risultava negativa per cellule atipiche e agli esami microbiologici. Dopo l’esecuzione, per ulteriore approfondimento, di PET total body che documentava “iperaccumuli confluenti ascellari profondi a sinistra”, si procedeva a biopsia linfonodale, con successiva diagnosi istologica di TB linfonodale (esame microscopico e colturale negativo).
RISULTATI: La diagnosi di Eritema di Bazin, sulla base dei dati rilevati, veniva da noi confermata, come espressione di una risposta immunologica secondaria a TB linfonodale (benché non dimostrata dall’isolamento colturale). Veniva pertanto instaurata terapia antitubercolare a 4 farmaci con INH, PZA, EMB e levofloxacina (LVF) nella fase di induzione (2 mesi) passando a 2 farmaci (INH+ LVF) nella fase di mantenimento, associata per alcuni periodi a terapia steroidea sistemica, con remissione totale del quadro clinico.
CONCLUSIONE: L’eritema di Bazin, benché raro, deve essere sospettato in presenza di lesioni cutanee nodulari croniche e differenziato da quadri clinici similari (es. eritema nodoso, panniculite lupica). A differenza dalla TB cutanea, non vi sono bacilli nelle lesioni. In questi casi è importante ricercare la TB sottostante ed intraprendere la terapia specifica associata a corticosteroidi, che spesso può essere prolungata anche per 9-12 mesi per la lenta risoluzione delle lesioni
PLASMABLASTIC LYMPHOMA OF ORAL CAVITY WITH GASTRIC AND BONE-MARROW INVOLVEMENT IN A YOUNG PATIENT WITH MOTHER-TO-CHILD TRANSMITTED HIV
No full textIntroduction: Incidence of non-Hodgkin lymphoma (NHL) is 200 times higher in HIV-positive patients than otherwise healthy persons. Plasmablastic lymphoma (PBL) accounts for less than 3% of all NHL in HIV patients and it’s associated with very poor prognosis. Immunodeficiency and HIV viremia are major risk factors for developing cancers, and high adherence to highly active antiretroviral therapy (HAART) has a protective role.
Case: We report here a case of 21-year-old HIV positive boy, presented to our Emergency Room for persisting dysphagia, vomit and weight-loss. He had a history of mother-to-child HIV transmission and multiple virological failures due to his poor HAART-adherence. On oral examination a mass in mandibular gingiva and one in hard palate were detected in association with oral candidiasis. Blood test revealed T-CD4+ cells 16/μl and HIV viral load 161.000 copies/μl. An esophagogastroduodenoscopy showed a 70 mm diameter mass on gastric small curvature. Total body CT scan documented also bilateral expansive lesions of maxillary sinus. Biopsies of gingival, palatine and gastric lesions were performed and all showed CD138+, CD20-, Epstein-Barr-virus (EBV)-associated PBL. Osteomedullary biopsy was positive for bone marrow involvement. The patient (classified as IV/B Ann-arbor stage) re-started HAART and initially underwent 2 CHOP regimens without benefits, thus DHAP chemotherapy was started, but also this proved ineffective. The patient received radiotherapy combined to corticosteroids and gemcitabine until his death, that occurred during a hospitalization for febrile neutropenia 6 months after PBL diagnosis.
Conclusions NHL is the most common HIV related cancer after Kaposi’s sarcoma. AIDS-related NHLs are predominantly aggressive high-grade B-cell lymphomas, such as PBL. This, like in our case, is characterized by weak/absent expression of conventional B-cell markers (CD20,CD45), by strong expression of plasma cell marker(CD138) and by EBV-relationship. Recognition of this entity by pathologists and clinicians is not easy but mandatory in order to start correct and early treatment. This lymphoma shows a tropism to the oral cavity, but involvement of areas other than head and neck (such as gastrointestinal tract) is rarely described. In literature, the apparent rarity of extra-oral sites and of such an advanced stage, as our patient, may be due to a closer follow up of HIV patients (among whom this lymphoma is more common) in addition to a lack of recognition. To the best of our knowledge, this is the first report of this entity in a vertically transmitted HIV-positive young man. This case highlights the increased risk of NHL in young people with vertical HIV infection, because of persistent immunodeficiency and viremia. Indeed low adherence to HAART, typical in this group of patients, might represent an emerging problem and NHL screening should be offered, in association with intervention to improve adherence, such as HAART simplification, if possible
SUCCESFULL TREATMENT OF PULMONARY NOCARDIOSIS WITH LINEZOLID
No full textNocardiosis is an opportunistic infection, with high mortality especially in immunocompromised patients. Up to one-third of patients with nocardiosis, however, are immunocompetent and the occurrence of the disease in these patients especially with chronic obstructive pulmonary disease (COPD) as the present case, can delay diagnosis and lead to rapidly respiratory failure.
A 82-years-old men, affected by COPD and chronic HBV-related hepatitis, was admitted in November 2012 to a regional hospital because of fever and cough (July 2012), with temporary benefit from a previously prescribed antibiotic treatment. He underwent chest High-Resolution-TC (HRTC) which showed lower left lobe pneumonia and was treated with ceftriaxone, with subsequent apyrexia. After discharging fever and cough relapsed and he was again admitted in hospital. HRTC showed widespread focal areas of pneumonia and a bronchoscopy was performed. Bronchial washing culture showed Nocardia spp colonies, but microbial identification was not done. A therapy with trimethoprim-sulphamethoxazole (TMP-SMX, TMP 240 mg-SMX 1200 mg TID) intravenously (i.v) was started, with initial slow improvement of clinical conditions, followed by relapse of fever and increasing values of white blood cells and reactive-C-protein (RCP, 15.2 mg/dl). The patient was thus admitted at our Institution in January 2013 and antibiotic therapy was intensified (TMP 240 mg-SMX 1200 mg QID plus amikacin 1 g QD i.v). Clinical conditions improved and WBC and RCP values decreased. A lung TC showed no differences with the previous one. After 2 weeks he developed respiratory failure; a chest x-rays showed a significant widespread pneumonia and RCP values increased; amikacin was ended and meropenem 4g daily i.v was started. One week after, no clinical, laboratory or radiologic improvement was observed; TMP-STX was discontinued and Linezolid 1200 mg daily i.v was started. Respiratory failure rapidly disappeared. After two weeks of treatment, clinical conditions markedly improved, RCP values decreased and radiological findings were less extended. Therapy is still ongoing. This will be switched orally and continued for 4-6 months, according to clinical and radiological findings.
Optimal antimicrobial treatment regimens for nocardiosis have not been firmly established. Moreover, as described for N. farcinica in Northern Italy, resistance to first-line regimens can occur, but most laboratories are not able to identify species and perform antibiogram, thus therapy can be quite empiric. TMP-SMX resistance, as this case remarks, can develop in vivo after initial effective treatment. Linezolid administration has been successfully reported for brain abscess and pneumonia caused by different Nocardia spp, because of its efficacy and good penetration in lung and CNS. Oral formulation is useful for long-lasting treatment as required, although bone-marrow and neurologic toxicity must be carefully evaluated
ASCESSO CEREBRALE PRIMITIVO DA ACTINOMYCES MEYERI IN GIOVANE DONNA IMMUNOCOMPETENTE.
No full textPREMESSA
L’actinomicosi è una rara malattia granulomatosa, lentamente progressiva, causata da batteri anaerobi Gram positivi della famiglia Actinomycetetaceae, appartenenti alla flora endogena del cavo orale, tratto alimentare e delle vie genitali femminili. Essi acquisiscono patogenicità quando superano le normali barriere anatomiche, facilitando l’invasione dei tessuti profondi, con localizzazioni in diversi siti (orocervicale, toracica, addominale, pelvica) e possibile disseminazione a distanza dell’infezione.
OBIETTIVO
Rare sono le descrizioni di casi di actinomicosi cerebrale, e di questi solo alcuni individuano in Actinomyces meyeri l’agente eziologico, responsabile invece di forme disseminate soprattutto nell’immunocompromesso.
Riportiamo il caso di una giovane donna affetta da ascesso cerebrale talamico, causato da A. meyeri trattato con successo con terapia medica e chirurgica.
RISULTATI
All’esordio il quadro era dominato da febbre (38°C), cefalea, vomito, confusione e segni di iniziale disfunzione cognitiva. In anamnesi si segnalava unicamente intervento odontoiatrico scarsamente invasivo, pochi mesi prima dell’esordio dei sintomi.
Gli esami ematici mostravano leucocitosi neutrofila (WBC 11840/mmc, N 10510) e aumento degli indici di flogosi (PCR 7.50 mg/dl). Una TC encefalo rivelava una lesione talamica espansiva, con ampia necrosi centrale ed edema perilesionale, suggestiva di secondarismo neoplastico, possibile tumore della serie gliale o ascesso cerebrale, confermata successivamente da RM encefalo. RX torace, ecografia addominale e ecocardiogramma trans-toracico risultavano nella norma. Emocolture, test per lue, Tubercolina, Quantiferon , HIV e toxoplasma negativi.
Gli esami colturali sul materiale intraoperatorio da drenaggio chirurgico della lesione, risultavano positivi per A. meyeri, confermati dall’esame istologico, che evidenziava la presenza di colonie actinomicotiche.
Veniva quindi instaurata, sulla base dell’ABG, terapia con ampicillina 5 g x 4/die e rifampicina 600 mg x 2/die (associata inizialmente a metronidazolo 500 mg x 3/die), proseguita a domicilio con ceftriaxone 2 g x 2 /die e poi con amoxicillina 1 g x 3/die, con scomparsa della febbre e normalizzazione del quadro neurologico. Il trattamento, dopo oltre 6 mesi, è tuttora in corso; una RM encefalo eseguita a 3 e 6 mesi di terapia ha mostrato scomparsa pressoché totale della lesione ascessuale.
CONCLUSIONI
L’actinomicosi è una patologia rara, ma severa, che va differenziata da altre condizioni come TB, nocardiosi (soprattutto in caso di HIV), ascessi batterici, neoplasie. I pochi casi descritti in letteratura riportano soprattutto forme orocervicali, addominali o disseminate, con coinvolgimento solo secondario del SNC e A. israelii è il patogeno più frequentemente isolato.
In questo caso la localizzazione primitiva, in assenza di focolai infettivi di partenza documentati, risulta particolarmente atipica, soprattutto in assenza di immunocompromissione.
Nonostante la disponibilità di diverse opzioni terapeutiche, la più efficace prevede l’utilizzo di dosi elevate di beta-lattamici (ampicillina 12-16 g/die) a cui abbiamo addizionato, per amplificarne l’effetto, la rifampicina, dotata anche di buona diffusione a livello del SNC.
A. meyeri, deve essere sempre investigato in presenza di fattori di rischio . La tempestività della diagnosi e la terapia appropriata, evitano la disseminazione e garantiscono l’outcome positivo
SIGNIFICANCE OF PROGNOSTIC VALUE OF ANEMIA IN PREDICTING OPPORTUNISTIC INFECTIONS IN HIV-INFECTED LATE PRESENTER PATIENTS STARTING ANTIRETROVIRAL THERAPY
No full textIntroduction
Anemia represents a well-known complication of HIV infection, especially in end-stage disease. Several factors could have an impact on Hemoglobin (HB) level in this disease, such as opportunistic infections, neoplasia and drugs. Many studies have demonstrated how developing of anemia is related with an higher incidence of AIDS, non-AIDS defining events or deaths, even if most of them concern to pre-HAART era; to our knowledge, few data examine the relationship between HB level at baseline and the risk of new AIDS events and new admissions to hospital among late presenters (LP) in the HAART-era.
Methods
We analyzed retrospectively patients’ data with new diagnosis of HIV and less than 350 T-CD4 cells/μL in period 2008-2013 in 2 HIV centers of North Italy; Santa Maria della Misericordia of Rovigo and Sant’Anna - University of Ferrara hospitals. Patients were sorted by HB level at baseline and divided in two groups: Group A and Group B, with and without anemia, respectively. Anemia was defined according the World Health Organization definition (Hb <13.0 g/dL in males, <12.0 g/dL in females). Chi-square Fisher’s exact test was emplojed to analyze differences among the two groups for new AIDS-events, new hospital admissions and virological failure. T-student test was used to evaluate differences among cell-T CD4+ in two groups.
Results
Of the 233 new diagnoses reported in 2008-2013 by the two centers, 47.6% were LP patients. Of these, 56 (71.8%) were males (22 Group A; 34 Group B) and 22 (28.2%) were females (12 Group A; 10 Group B). The median age of LP was 43 years (IQR 35-52) in Group A and 43 (IQR 36-52) in Group B. Risk factors related with HIV transmission were HET in 45 patients (20 Group A, 25 Group B), MSM in 12 (6 Group A, 6 Group B), IDU in 3 (2 Group A, 1 Group B), Other/Unknown 18 (6 Group A, 12 Group B). Of the 233 new diagnoses, 111 (47.6%) were LP; of these, (7.2%) died. Due to lack of data, 25 patients were excluded. 34 LP patients (43.6%) had anemia at diagnosis, compared to 44 (56.4%) patients without anemia. Total median values of T-CD4+-cells observed at the moment of diagnosis of HIV was 116/μL (IQR 59-217); in Group A, 74/μL (IQR 50-147) compared to 180/μL (IQR 76-245) (p0,05). Virological failure occurred in 11 patients (32.3%) in Group A, 9 (20.5%) in Group B (p>0,05). After beginning of HAART, 9 patients developed at least one new AIDS event (total number of new AIDS-events was 13) in Group A, 1 (1 new AIDS events) in Group B (p 0,05)
Conclusion
Despite beginning of HAART, patients who present late at diagnosis continue to have high risk of developing new AIDS-events or to be re-admitted at hospital. Both patient groups at moment of diagnosis had a median of T-CD4 cells count <200/μL, thus being at risk of developing AIDS. HB value before starting HAART seems to have an important prognostic role to pinpoint, among LP, who has an higher risk of new AIDS events. For this reason LP with anemia should be monitored with a closer follow-up to identify as soon as possible worsening of health-condition
DELAY IN DIAGNOSIS AMONG AIDS-PRESENTER IN TWO HOSPITALS IN THE NORTH EAST OF ITALY
No full textIntroduction. Most common causes of death in HIV patients in high income countries are related to late presentation (LP), defined as presenting for care with a CD4 count <350 cell/μL or with an AIDS-defining event. Data by ECDC illustrate that during years 2008-2012 in Italy, 5382 AIDS cases occurred with 2307 AIDS-related death. LP is associated to reduced life expectancy, higher risk of HIV transmission and economic implications. In this preliminary study we aimed to calculate the delay in HIV diagnosis in patients with symptoms of AIDS-disease and to characterize AIDS-events more frequently related to delay.
Methods We retrospectively analyzed data of patients with new HIV diagnosis and less than 350 T-CD4 cells/μL in period 2008-13 in Rovigo and Ferrara hospitals; furthermore, we calculated the days between the first contact with any health care provider because of onset of AIDS-disease symptoms and diagnosis of HIV/AIDS. We also evaluated risk factors for delay in diagnosis.
Results. An overall of 233 new diagnoses was recorded by the two centers and 47.6% were LP. Of these, 33.3% were AIDS-presenter and 7.2% died. Median age of LP was 43 ys (IQR 35-52); 72.1% males; 18.9% non-nationals. Risk factors related with HIV transmission were HET 55% (n.45), MSM 18.9% (n.12), IDU 5.4% (n.3), unknown, 20.7% (n. 18). Among 37 AIDS-presenters (M 76%, F 24%; HET 60%, MSM 16.5%, unknown, 23.5%), we recorded the following AIDS events: 10 wasting syndromes, 9 PCP, 7 esophageal candidiasis, 6 Kaposi’s Sarcoma (KS), 5 CMV disease, 3 neurotoxoplasmosis (NT), 3 Non Hodgkin Lymphomas, 3 Progressive Multifocal Leukoencephalopathy, 2 TB, 1 AIDS dementia complex (ADC), 1 Atypical mycobacteriosis, 1 Candida pneumonia, 1 Cryptococcosis*. Of these patients, 24,5% had more than 1 AIDS event at diagnosis. We found a median delay of 48,5 days (IQR 16-154), which was maximum in patients with (180 days) and KS (150 d) and minimum in those with NT, (10 d) and TB (9 d). Mortality among AIDS presenters was 23%. There were no significant differences in delay of diagnosis between national and non-national, male and female and risk factors.
Conclusions In our centers, LP demographic features agree with national data. Despite the presence AIDS events, HIV test was performed with a median delay of more than 45 d; some conditions such as ADC or KS were associated with a lateness of 6-5 months respectively. By contrast, TB seemed to be linked with a quicker HIV-test performance, probably due to physicians’ awareness of the epidemiological relevance of coinfection TB-HIV. Typical AIDS events, as KS and esophageal candidiasis, were associated with a relevant delay. “Late testing” even in presence of an AIDS event shows how nowadays HIV is a less perceived issue. Our study points out the need of improving physicians’ consciousness about AIDS to detect it and starting HAART together with other specific therapy as soon as possible
- …
